Journal article

Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study

Nabil Seery, Sifat Sharmin, Vivien Li, Ai-Lan Nguyen, Claire Meaton, Roberts Atvars, Nicola Taylor, Kelsey Tunnell, John Carey, Mark P Marriott, Katherine A Buzzard, Izanne Roos, Chris Dwyer, Josephine Baker, Lisa Taylor, Kymble Spriggs, Trevor J Kilpatrick, Tomas Kalincik, Mastura Monif

CNS DRUGS | ADIS INT LTD | Published : 2021


BACKGROUND: Ocrelizumab safety outcomes have been well evaluated in clinical trials and open-label extension (OLE) studies. However, risk factors for infection in patients with multiple sclerosis (MS) receiving ocrelizumab have not been extensively studied in the real-world setting. OBJECTIVE: The aim of this study was to examine factors determining risk of self-reported infections and antimicrobial use in patients receiving ocrelizumab for MS. METHODS: A retrospective, observational cohort study was conducted in patients receiving ocrelizumab at the Royal Melbourne Hospital. Infection type and number were reported by patients, and the associations of potential clinical and laboratory risk f..

View full abstract